CAS |
No.108237-91-8 |
英文名称 |
RCGD423 |
别名 |
;RCGD-423;RCGD423; |
分子式 |
C15H11BrN2S |
分子量 |
331.23 |
溶解性 |
Soluble in DMSO ≥10mg/mL |
纯度 |
≥98% |
外观(性状) |
Light yellow to yellow Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
SMILES |
C1=CC=C(C=C1)C2=CSC(=N2)NC3=CC=C(C=C3)Br |
InChIKey |
OUFYYVAASPLOAA-UHFFFAOYSA-N |
InChI |
InChI=1S/C15H11BrN2S/c16-12-6-8-13(9-7-12)17-15-18-14(10-19-15)11-4-2-1-3-5-11/h1-10H,(H,17,18) |
PubChem CID |
4456143 |
靶点 |
gp130 |
通路 |
Immunology & Inflammation |
背景说明 |
RCGD423 是 gp130 调节剂。 |
生物活性 |
RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair.[1] |
In Vitro |
RCGD423 increased proliferation while reducing Apoptosis and hypertrophic responses in adult chondrocytes in vitro.[1] |
In Vivo |
In a rat partial meniscectomy model, RCGD 423 greatly reduced chondrocyte hypertrophy, loss and degeneration while increasing chondrocyte proliferation beyond that observed in response to injury. Moreover, RCGD 423 improved cartilage healing in a rat full-thickness osteochondral defect model, increasing proliferation of mesenchymal cells in the defect and also inhibiting breakdown of cartilage matrix in de novo generated cartilage.[1] |
数据来源文献 |
[1]. Shkhyan R, et al. Drug-induced modulation of gp130 signalling prevents articular cartilage degeneration and promotes repair. Ann Rheum Dis. 2018 May;77(5):760-769. |
规格 |
5mg 10mg 25mg 50mg 100mg |
单位 |
瓶 |